Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Viewpoints - The company reported a revenue of 5.54 billion, representing a year-on-year growth of 57%, and a net profit of 2.06 billion, with a year-on-year increase of 42%. The adjusted net profit reached 2.15 billion, reflecting a growth of 46.5% [2][4] - The board proposed a final dividend of 0.60 per share and a special dividend of 0.59 per share [2][4] - The main brand, "可复美" (Kefumei), continued to show high growth, while the sub-brand "可丽金" (Kelin) optimized its structure [8] Revenue and Profit Analysis - In 2024, the main brand "可复美" achieved a revenue of 4.54 billion, growing by 63%, while "可丽金" generated 0.84 billion, with a growth of 36% [8] - The company’s gross profit margin decreased by 1.5 percentage points due to the expansion of product categories, while the net profit margin was at 37.2%, still high within the industry [8] - In the second half of 2024, the company achieved a revenue of 3 billion, with a year-on-year growth of 56% [8] Product and Market Development - The company is actively expanding its research in the field of recombinant collagen and has made progress in medical device certifications [8] - The company received exclusive patent authorization for various types of recombinant collagen, enhancing its patent portfolio [8] Future Profit Projections - The adjusted net profit for 2025-2027 is projected to be 2.59 billion, 3.11 billion, and 3.74 billion respectively, with corresponding valuations of 25, 21, and 17 times [8]

Investment Rating - The report maintains a "Buy" rating for the company, with an expected price increase of over 15% in the next 6-12 months [4]. Core Insights - The company achieved a contract sales amount of approximately 363 billion yuan for self-invested projects in Q1 2025, with a cumulative total of 524 billion yuan for the group [2]. - In 2024, the company reported revenue of 1585.46 billion yuan, a year-on-year increase of 20.7%, but the net profit attributable to shareholders decreased by 48.8% to 15.96 billion yuan [2]. - The decline in net profit is attributed to losses from joint ventures and increased impairment provisions totaling 49.17 billion yuan, which is 28.82 billion yuan higher than the previous year [3]. - The company’s property sales revenue reached 1470.2 billion yuan in 2024, accounting for 92.7% of total revenue, reflecting a year-on-year growth of 21.9% [3]. - The company’s total contract sales amount for 2024 was 2768 billion yuan, a decrease of 8.1% year-on-year, with self-invested sales down 11.6% [3]. - The company has a strong market presence in core cities, with 79% of sales coming from first and second-tier cities, and it ranks first in market share in eight cities [3]. Financial Performance - The company’s total land reserve consists of 146 projects with a total buildable area of 27.47 million square meters, of which 18.43 million square meters are for sale [4]. - The company’s financing channels remain robust, with domestic bond issuance of 12.531 billion yuan in 2024 and a total interest-bearing debt financing cost of 3.7%, down 40 basis points year-on-year [4]. - The projected net profit for 2025, 2026, and 2027 is adjusted to 1.83 billion yuan, 2.30 billion yuan, and 2.74 billion yuan, respectively, with year-on-year growth rates of 14.6%, 25.7%, and 19.1% [4]. - The company’s current stock price corresponds to a PE ratio of 13.2, 10.5, and 8.8 for the years 2025, 2026, and 2027, respectively [4]. Market Conditions - The report notes that the real estate market continues to face challenges, including lower-than-expected policy implementation and ongoing sales sluggishness [5].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage, highlighting a value reassessment amid the PC replacement cycle [5][87]. Core Insights - The company is positioned to benefit from the ongoing PC replacement cycle, particularly as Windows 10 support ends in October 2025, which may drive demand for new devices [7][40]. - The AI transformation across its three main business segments (IDG, ISG, SSG) is expected to enhance growth and profitability [11][74]. - The report anticipates significant revenue growth in the commercial PC sector, with a projected shipment of 138 million units in 2025, reflecting a 4.3% year-on-year increase [59][60]. Summary by Sections Market Performance - The closing price of the stock is HKD 7.50, with a market capitalization of approximately HKD 93 billion [3]. Financial Forecasts and Valuation - Revenue projections for the company are as follows: - 2023: USD 61.95 billion - 2024: USD 56.86 billion - 2025E: USD 67.65 billion - 2026E: USD 74.63 billion - 2027E: USD 80.35 billion - Net profit forecasts are: - 2023: USD 1.68 billion - 2024: USD 1.10 billion - 2025E: USD 1.62 billion - 2026E: USD 1.80 billion - 2027E: USD 2.05 billion - The report indicates a projected PE ratio of 7X for 2026, which is below the average PE of comparable companies [6][87]. Business Analysis - The company operates through three main segments: - Intelligent Device Group (IDG): Contributes 69% of revenue, with a projected growth rate of 12% from 2025 to 2027. - Infrastructure Solutions Group (ISG): Accounts for 20% of revenue, with a forecasted growth of 52% in 2025. - Solutions and Services Group (SSG): Represents 11% of revenue, with expected growth of 11% in 2025 [19][21][83]. Key Growth Drivers - The report emphasizes the importance of the PC replacement cycle and the demand for AI-integrated PCs (AIPC) as significant growth drivers for the company [11][59]. - The company’s strategy includes leveraging its AI capabilities to enhance user experience and drive demand in both commercial and consumer markets [57][60]. Strategic Initiatives - The company has adopted a strategic framework called "One Horizontal and Five Verticals" to support its AI infrastructure, aiming to provide comprehensive solutions across various sectors [74]. - The SSG segment focuses on local market needs, enhancing its service offerings to meet the demands of various industries [80].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 60, indicating a potential upside of 55% from the current price of HKD 38.7 [2][5]. Core Insights - The commercialization of CM310 is progressing well, with satisfactory sales performance in the first quarter. The company aims to expand its commercialization team from over 300 to 500 by the end of 2025, focusing on hospital access and negotiations for insurance coverage [3]. - The next-generation dual antibody CM512 is a key product in the research pipeline, with Phase 1 data expected in Q3 2025. The company is also advancing overseas clinical trials for several molecules, with data expected in 2026 [4][10]. - The company has set a sales guidance of RMB 500 million for the year, with significant contributions expected in the second half [3]. Summary by Sections Commercialization Progress - CM310's commercialization team is currently over 300 members, with plans to expand to 500 by the end of 2025. The team is focused on increasing hospital access and engaging with dermatologists and ENT specialists [3]. - The first quarter sales performance was satisfactory, with 29 provinces already having access to CM310. The pricing strategy positions CM310 competitively against existing treatments [3]. Research and Development - CM512, targeting TSLP and IL-13, is in the second position globally for development. The company is focusing on autoimmune and respiratory indications, with ongoing trials in China and plans for international trials [4][10]. - The company anticipates multiple overseas data readouts in 2026, including for CM901 and CM336 [10]. Financial Projections - Revenue is projected to grow significantly, with estimates of RMB 354 million in 2023, increasing to RMB 2.249 billion by 2027, reflecting a compound annual growth rate of 46% [12][14]. - The company expects to incur losses in the coming years, with net losses projected to peak at RMB 737 million in 2026 before improving [12][14].

证券研究报告 医药生物 | 生物制品 港股|公司点评报告 hyzqdatemark 2025 年 04 月 10 日 | 基本数据 | 2025 | 年 04 | 月 | 09 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 42.20 | | | 一年内最高/最低（港 | | | 52.15/28.65 | | | | 元） | | | | | | | 总市值（百万港元） | | | | 69,552.86 | | | 流通市值（百万港元） | | | | 69,552.86 | | | 资产负债率（%） | | | | 39.28 | | | 资料来源：聚源数据 | | | | | | 信达生物(01801.HK) 投资评级： 买入（维持） ——超预期实现盈利，全球化布局加速推进 投资要点： 风险提示：竞争格局恶化风险、销售不及预期风险、行业政策风险等。 | 盈利预测与估值（人民币） | | | | | | | --- | --- | --- | --- | --- | --- | | | 2023 | 2024 | 2025E ...

Investment Rating - The investment rating for the company is Neutral with a target price of HKD 16.25, indicating a potential upside of 11.9% from the current closing price of HKD 14.52 [2][7]. Core Insights - The company is expected to maintain stable revenue and gross margin performance in 2025, with a projected revenue of RMB 29,080 million, reflecting a year-on-year growth of 1.4% [3][6]. - The management anticipates that the gross margin will remain stable or slightly improve, supported by product mix optimization and operational cost management [7][8]. - The running category has shown significant growth, with retail sales increasing by 25% and total sales of the three core IPs exceeding 10.6 million pairs [7][8]. Financial Overview - Revenue for 2024 is projected at RMB 28,676 million, a 3.9% increase from 2023, with footwear sales contributing RMB 14,300 million, up 7% [6][8]. - The net profit for 2024 is expected to be RMB 3,013 million, with a net profit margin of 10.5% [6][8]. - The company plans to maintain a dividend payout ratio of 50%, increasing the dividend per share to RMB 0.5848 [7][8]. Operational Performance - The company has successfully optimized its channels, closing 83 inefficient stores while increasing the number of Li Ning YOUNG stores by 40 [7][8]. - E-commerce revenue has increased, now accounting for 31% of total revenue, highlighting its role as a key growth driver [7][8]. - The company aims to strengthen its leading position in the running category while nurturing emerging categories such as outdoor and tennis [7][8]. Financial Projections - The projected financials for the next few years include: - Revenue: RMB 29,080 million in 2025, RMB 30,809 million in 2026, and RMB 32,855 million in 2027 [6][13]. - Net profit: RMB 2,971 million in 2025, RMB 3,375 million in 2026, and RMB 3,871 million in 2027 [6][13]. - The company’s gross margin is expected to be 49.5% in 2025, with a slight increase to 50% by 2027 [14].

证券研究报告 | 2025年04月10日 资料来源：Wind、国信证券经济研究所预测 注：摊薄每股收益按最新总股本计算 绿城管理控股（09979.HK） 优于大市 竞争加剧导致业绩承压 归母净利-18%，政府代建承压。2024 年公司实现营业收入 34 亿元，同比增 长 4%；实现归母净利润 8 亿元，同比下降 18%。公司增收不增利的原因主要 为毛利率下滑，以及计提信贷减值约 1 亿元。分类别看，公司商业代建收入 为 28 亿元，同比增长 17%,收入占比增长 9pct 至 80%；政府代建业务收入 6.3 亿元，同比下降21%。2024 年公司整体毛利率为49.6%，较上年末下降2.6pct， 其中商业代建毛利率为 51%，政府代建毛利率为 40%，分别较上年末下降 1、 5pct。 规模稳中有进，新拓结构优化。截至 2024 年末，公司业务分布已覆盖 130 个城市，合约总建筑面积达 1.3 亿平方米，同比增长 5%，当期在建面积 0.5 亿平放米，同比增长 3%，保持行业龙头地位。在全国化布局下，公司市占率 稳步扩大，2024 年新签代建规模 3649 万平方米，新签市占率 22.1%，较上 年提升 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - The company achieved a net profit of 2.15 billion, representing a year-on-year increase of 46%, which aligns with expectations [1] - Revenue for the year 2024 is projected to be 5.54 billion, a year-on-year increase of 57%, with a net profit of 2.06 billion, up 42% [1] - The company is expected to continue its growth trajectory, with revenue forecasts of 7.07 billion, 8.71 billion, and 10.45 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 28%, 23%, and 20% [5] Financial Performance - The adjusted net profit for 2024 is projected at 2.15 billion, a 46% increase year-on-year, which meets expectations [1] - The gross margin for 2024 is 82.1%, a decrease of 1.5 percentage points year-on-year, while the net profit margin is 37.2%, down 4 percentage points [2] - The company plans to distribute a total dividend of 1.19 per share, with a payout ratio of 60% [1] Business Segmentation - The main brand, Kefu Mei, generated revenue of 4.54 billion, a year-on-year increase of 63%, accounting for 82% of total revenue [3] - Online sales accounted for 72% of total revenue, with a year-on-year growth of 70% [3] - The second brand, Keli Jin, saw revenue of 840 million, a 36% increase year-on-year [3] Future Outlook - The company is positioned as a leader in the collagen protein sector, with strong growth in its main brand and accelerating growth in its second brand [5] - The company is expected to maintain a strong market presence with significant online sales growth and expansion into new retail locations [4]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [6]. Core Views - The company focuses on differentiated small molecule drug development, with its core asset, Pimicotinib, expected to be commercialized soon [6][12]. - The company achieved its first annual profit in 2024, with a net profit of 28.3 million yuan and total revenue of 504 million yuan, primarily from licensing agreements [6][23]. - The company has a robust pipeline with 19 oncology products, 12 of which are in clinical development [6][12]. Summary by Sections Section 1: Commitment to Differentiated Small Molecule Development - The company is dedicated to developing differentiated small molecule therapies for oncology, with 12 clinical candidates in its pipeline [12]. - The management team has extensive experience in drug development, enhancing the company's innovation capabilities [18]. - A stock repurchase plan of up to 200 million HKD is set to start in 2025, reflecting management's confidence in future growth [21]. - The company reported its first annual profit in 2024, with a strong cash reserve of 1.959 billion yuan [23]. - The core product, Pimicotinib, is expected to submit applications for market approval in China and the U.S. in 2025 [26]. Section 2: CSF-1R Pimicotinib for TGCT - Pimicotinib has reached the primary endpoint in its Phase 3 trial for treating TGCT, with plans to submit market applications in 2025 [30][32]. - The drug shows promising efficacy and safety in treating chronic graft-versus-host disease (cGvHD) in its Phase 2 trials [38][44]. Section 3: FGFR Small Molecule Inhibitors - The company has a multi-faceted approach to FGFR inhibitors, with ABSK011 entering pivotal Phase 2/3 trials for liver cancer [7]. - ABSK061, the first FGFR2/3 inhibitor in clinical trials, is expected to advance in 2025 for various indications [7]. Section 4: Oral PD-L1 Inhibitor ABSK043 - The global PD-(L)1 market is projected to exceed 50 billion USD in 2024, with the company exploring the potential of its oral PD-L1 inhibitor [4]. Section 5: Early Pipeline and Dual-Antibody ADC Platform - The company maintains a rich early-stage pipeline, which is crucial for its long-term growth [7].

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [6]. Core Views - The company focuses on differentiated small molecule drug development, with its core asset, Pimicotinib, expected to be commercialized soon [6][12]. - The company achieved its first annual profit in 2024, with a net profit of 28.3 million yuan and total revenue of 504 million yuan, primarily from licensing agreements [6][23]. - The company has a robust pipeline with 19 oncology products, 12 of which are in clinical development, and has established partnerships with major pharmaceutical companies [6][12]. Summary by Sections Section 1: Commitment to Differentiated Small Molecule Development - The company is dedicated to developing differentiated small molecule therapies for oncology, with 12 clinical candidates in its pipeline [12]. - The management team has extensive experience in drug development, enhancing the company's innovation capabilities [19]. - A stock buyback plan of up to 200 million HKD is set to start in 2025, reflecting management's confidence in future growth [21]. - The company reported its first annual profit in 2024, with a cash reserve of 1.959 billion yuan [23]. - The core product, Pimicotinib, is expected to submit applications for market approval in China and the U.S. in 2025 [28]. Section 2: Pimicotinib for TGCT - Pimicotinib has reached the primary endpoint in its Phase 3 trial for treating TGCT and is expected to submit market applications in 2025 [30][33]. - The drug shows promising efficacy and safety in treating cGvHD, with a complete Phase 2 data disclosure expected in 2025 [39][45]. Section 3: FGFR Small Molecule Inhibitors - The company is advancing its FGFR4 inhibitor, ABSK011, into pivotal Phase 2/3 trials for liver cancer [7]. - ABSK061, a FGFR2/3 inhibitor, is set to enter clinical trials for achondroplasia in 2025 [7]. Section 4: Oral PD-L1 Inhibitor Development - The global PD-(L)1 market is projected to exceed 50 billion USD in 2024, with the company exploring the potential of its oral PD-L1 inhibitor [4]. Section 5: Early Pipeline and Dual-Antibody ADC Platform - The company maintains a rich early-stage pipeline, which is crucial for its long-term growth [7].